An Early Phase 1 interventional study of Ivabradine (single oral dose) in Healthy Adult, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 19 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by University of British Columbia · Early Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Motor Activity by University of British Columbia — 24 open to participants now, 26 under way, none of them phase 3. Motor Activity · University of British Columbia.
Among the 96 studies in Motor Activity by University of British Columbia, this one is the 71st largest by planned enrollment of the 92 interventional ones that give a count, is one of 7 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 9 of the 25 other live ones, and was the 95th registered.
9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.
Browse Motor Activity studies →24 of the 96 studies in Motor Activity by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:
University of British Columbia · Sites in Canada
Ages 50+
University of British Columbia · Sites in Canada
Ages 19–35 · Healthy volunteers
University of British Columbia · Sites in Canada
Ages up to 99
University of British Columbia · Sites in Canada
Ages 19–39 · Healthy volunteers
University of British Columbia · Sites in Canada
Ages 50+
By country, each count listing its studies:
Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.
This study: 19 Years to 79 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 60 across 8,412 interventional studies indexed under Motor Activity.
Median enrollment 61 across the 92 interventional studies, 35 across the 4 observational. Of the 58 that completed or were terminated, 12 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
11 of the studies in Motor Activity by University of British Columbia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07717710University of British ColumbiaIvabradine for Heart Rate Reduction During Exercise in Healthy Adults | 2026-12 |
| NCT06195423University of British ColumbiaStopping OsteoARthritis After an ACL Tear | 2026-12-30 |
| NCT07443293University of British ColumbiaIMPACT 360 for Parkinson's Disease | 2026-12-31 |
| NCT04299945University of British ColumbiaEffects of Drinking Beetroot Juice on Exercise Performance in Patients With Fibrotic Interstitial Lung Disease | 2026-12-31 |
| NCT07212712University of British ColumbiaThe Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 96 studies in Motor Activity by University of British Columbia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
During exercise, working muscles require more oxygen. The heart meets this demand in two ways: by beating faster (heart rate) and by pumping more blood with each beat (stroke volume). Heart rate increases steadily with exercise intensity until exhaustion, but the amount of blood pumped with each beat tends to plateau at moderate intensities. Why the amount of blood pumped with each beat becomes limited before heart rate, however, is not well understood.
Studying these mechanisms is difficult because most drugs that lower heart rate also affect how strongly the heart pumps, making it hard to separate the two effects. One medication that can help with this is ivabradine, which is used to treat people with heart disease who have high resting heart rates. It slows the heart rate without changing how strongly the heart pumps.
This study will investigate whether ivabradine lowers heart rate during exercise in healthy younger and older adults, and whether a higher dose lowers heart rate more. The results will help us better understand how heart rate influences the heart's ability to supply oxygen to the body during exercise, and what limits the ability to exercise as people age.
Participants will:
Heart rate and stroke volume are generally considered as two independent factors which influence cardiac output, yet they are interlinked by cellular (e.g., calcium handling) and hemodynamic (e.g., diastolic pressure decay) mechanisms. Delineating how heart rate and stroke volume influence cardiac output and exercise capacity, even within healthy individuals, has historically been experimentally difficult as pharmacologic perturbations, such as beta-adrenergic antagonists, influence both heart rate and heart muscle performance. Ivabradine selectively reduces heart rate in a dose-dependent manner, without impacting myocardial contractility, cardiac afterload, or venous return. However, it has largely been studied in clinical outcome trials in adults with heart failure, or safety studies in younger healthy adults. As such, there is a knowledge gap on how ivabradine influences heart rate and exercise capacity in healthy younger and older adults.
Study Purpose To characterize the effects of two single doses of ivabradine (7.5 mg and 12.5 mg) on heart rate during incremental exercise in younger and older healthy adults.
Exploratory Aim To assess the safety and tolerability of two single doses of ivabradine (7.5 mg and 12.5 mg) in younger and older healthy adults.
Hypothesis Ivabradine will produce dose-dependent reductions in peak exercise heart rate and heart rate/work-rate relationships (anticipated to be approximately 10-15%, on average).
Research Design Unblinded, non-randomized, repeated measures design.
Study Visits Visit 1 (1.5 hours): Screening, consent, assessments of anthropometrics, seated heart rate and blood pressure, a resting 12-lead electrocardiogram, and a cardiopulmonary exercise test with 12-lead electrocardiogram. Pre-menopausal females will also be required to complete a urine pregnancy test and confirm a negative result prior to participation.
Visits 2 and 3 (4 hours each): A single oral dose of ivabradine will be administered at each visit: 7.5 mg at Visit 2 and 12.5 mg at Visit 3. Doses are administered in this fixed order so that all participants are observed at the lower dose before proceeding to the higher dose.
Following drug administration, participants will be seated and observed for 90 minutes with continuous heart rate monitoring and blood pressure recorded at 15-minute intervals. Participants will then complete an incremental exercise test on a cycle ergometer with 12-lead ECG monitoring, following the same work-rate protocol used in Visit 1. Following exercise, participants will be seated and observed for 120 minutes with continuous heart rate monitoring and blood pressure recorded at 15-minute intervals.
Statistical Analysis Data will be analyzed using SPSS Statistics (v.30, IBM Inc). Normality will be assessed by the Shapiro-Wilk test. Omnibus testing will be conducted using analysis of variance (ANOVA), the Friedman test, or the Kruskal-Wallis test with significant effects tested post hoc. If all compared groups or conditions approximate a normal distribution, data will be presented as mean ± standard deviation with paired comparisons made using t-tests. Otherwise, data will be presented as median (inter-quartile range) with paired comparisons made using the Mann-Whitney U or Wilcoxon Signed Rank tests. Associations will be explored with Pearson correlations and linear regression.
Sample Size Justification Based on existing literature describing the effect of ivabradine on heart rate during exercise in healthy adults, a sample size of 20 provides 95% power to detect a 5 beats per minute difference between 7.5 mg and 12.5 mg trials, assuming a standard deviation of 5 beats per minute and a two-tailed alpha of 0.05 adjusted for three post-hoc paired t-tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants receive two single oral doses of ivabradine in a fixed sequence across separate experimental visits.
Drug: Ivabradine (single oral dose)
A single oral dose of ivabradine is administered at each experimental visit, in a fixed order: 7.5 mg at Visit 2 (one 7.5 mg tablet), and 12.5 mg at Visit 3 (one 7.5 mg + one 5 mg tablet). Ivabradine is a selective hyperpolarization-activated cyclic nucleotide-gated transmembrane (HCN4) channel inhibitor that reduces heart rate without affecting myocardial contractility.
Heart rate, peak
Highest heart rate achieved during the cardiopulmonary exercise test.
Time frame: Within 30 minutes of exercise onset
Heart rate, resting
Average heart rate over the 15 minutes of rest prior to the cardiopulmonary exercise test.
Time frame: Within 15 minutes prior to exercise onset
Heart rate/work rate
Highest heart rate divided by the highest work rate achieved during the cardiopulmonary exercise test.
Time frame: Within 30 minutes of exercise onset
Incidence of visual symptoms
Frequency of self-reported visual symptoms (phosphenes) assessed by standardized symptom questionnaire at 15-minute intervals during pre- and post-exercise observation periods.
Time frame: Within 4 hours post-dose administration
Incidence of headache
Frequency of self-reported headache assessed by standardized symptom questionnaire at 15-minute intervals during pre- and post-exercise observation periods.
Time frame: Within 4 hours post-dose administration
Incidence of bradycardia
Frequency of: (1) resting heart rate \<60 beats per minute; (2) resting heart rate \<50 beats per minute; and (3) a decrease in resting heart rate of \>10 beats per minute from pre-dose baseline, assessed by continuous heart rate monitoring during pre- and post-exercise observation periods.
Time frame: Within 4 hours post-dose administration
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Dec 2026, 2 months after the start.
Of 73 non-industry phase 1 interventional studies under Motor Activity, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 2 months is below that.
Counting every sponsor, half of 75 studies reached it within 20 months; a quarter within 11 and three quarters within 43.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivabradine
University of British Columbia →